| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BAF180; hPB1; PB1; Pbrm1; polybromo 1; Polybromo-1D;;PB1 |
| WB Predicted band size | 193 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PB1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于PBRM1抗体的代表性文献(虚构示例，仅供参考格式)：
1. **文献名称**：*PBRM1 loss defines a non-canonical renal cell carcinoma subtype with immune-infiltrative phenotype*
**作者**：Smith A, et al.
**摘要**：研究利用PBRM1特异性抗体进行免疫组化分析，发现PBRM1缺失的肾癌患者肿瘤微环境中T细胞浸润增加，提示其作为免疫治疗生物标志物的潜力。
2. **文献名称**：*Structural basis for PBRM1 bromodomain binding to histone H3K36me2*
**作者**：Chen L, et al.
**摘要**：通过X射线晶体学结合PBRM1抗体验证蛋白表达，揭示了PBRM1溴结构域与组蛋白修饰H3K36me2的结合模式，阐明其在染色质重塑中的分子机制。
3. **文献名称**：*PBRM1 mutations alter SWI/SNF complex assembly and enhance sensitivity to HDAC inhibitors*
**作者**：Wang Y, et al.
**摘要**：采用Western Blot和免疫沉淀技术(使用PBRM1抗体)，证明突变导致SWI/SNF复合体稳定性下降，并增加肿瘤细胞对表观遗传药物的敏感性。
(注：以上为模拟内容，实际文献需通过PubMed/Google Scholar检索关键词“PBRM1 antibody”或“PBRM1 immunohistochemistry”获取。)
The PBRM1 (Polybromo-1) gene encodes BAF180. a core subunit of the PBAF (PB1-associated factor) chromatin remodeling complex within the SWI/SNF family. This complex regulates gene expression by modifying chromatin structure, influencing processes like DNA repair, cell cycle control, and differentiation. PBRM1 contains six bromodomains that recognize acetylated lysine residues on histones, linking chromatin remodeling to epigenetic regulation.
Mutations or loss of PBRM1 are strongly associated with cancer, particularly clear cell renal cell carcinoma (ccRCC), where it acts as a tumor suppressor. Dysfunctional PBRM1 disrupts transcriptional programs, promoting tumorigenesis and altering therapeutic responses. Its expression is also implicated in other cancers, including bladder and ovarian cancers.
PBRM1 antibodies are critical tools for detecting protein expression and localization in research. They enable applications like immunohistochemistry (IHC), Western blotting, and immunofluorescence to study PBRM1's role in cancer biology, chromatin dynamics, and drug resistance. Additionally, these antibodies help validate PBRM1 as a potential biomarker for prognosis or targeted therapy. Recent studies explore its interaction with immune checkpoint pathways, highlighting its relevance in immunotherapy. However, antibody specificity remains a challenge due to PBRM1's structural complexity and homology with other bromodomain proteins. Validated antibodies are essential for advancing mechanistic and translational research in epigenetics and oncology.
×
